$141.03 Million in Sales Expected for Medidata Solutions, Inc. (MDSO) This Quarter
Analysts expect that Medidata Solutions, Inc. (NASDAQ:MDSO) will report sales of $141.03 million for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Medidata Solutions’ earnings. The highest sales estimate is $142.34 million and the lowest is $140.40 million. Medidata Solutions reported sales of $120.06 million during the same quarter last year, which indicates a positive year-over-year growth rate of 17.5%. The firm is scheduled to announce its next earnings report on Tuesday, October 24th.
On average, analysts expect that Medidata Solutions will report full year sales of $141.03 million for the current fiscal year, with estimates ranging from $550.10 million to $558.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $652.31 million per share, with estimates ranging from $642.33 million to $669.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.03. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. The business had revenue of $137.41 million for the quarter, compared to the consensus estimate of $134.28 million. During the same period last year, the business posted $0.24 EPS. The business’s revenue was up 19.9% compared to the same quarter last year.
Several analysts have recently issued reports on MDSO shares. BidaskClub cut Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Wednesday, June 14th. KeyCorp increased their price objective on Medidata Solutions from $71.00 to $74.00 and gave the company an “overweight” rating in a research note on Thursday, May 11th. SunTrust Banks, Inc. increased their price objective on Medidata Solutions from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, June 27th. J P Morgan Chase & Co increased their price objective on Medidata Solutions to $87.00 and gave the company an “overweight” rating in a research note on Tuesday, July 18th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $94.00 price objective (up from $77.00) on shares of Medidata Solutions in a research note on Monday, July 10th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company. Medidata Solutions has an average rating of “Buy” and a consensus target price of $78.17.
COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/08/11/141-03-million-in-sales-expected-for-medidata-solutions-inc-mdso-this-quarter.html.
Shares of Medidata Solutions (NASDAQ:MDSO) traded up 0.55% on Friday, hitting $73.11. The stock had a trading volume of 261,094 shares. The stock has a 50 day moving average of $78.13 and a 200 day moving average of $66.11. Medidata Solutions has a 12-month low of $46.10 and a 12-month high of $85.92. The firm has a market cap of $4.14 billion, a price-to-earnings ratio of 118.11 and a beta of 1.79.
In other Medidata Solutions news, Director Robert Taylor sold 5,639 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $73.46, for a total transaction of $414,240.94. Following the transaction, the director now owns 54,372 shares of the company’s stock, valued at $3,994,167.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Michael L. Capone sold 5,000 shares of the firm’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $69.46, for a total value of $347,300.00. Following the transaction, the chief operating officer now directly owns 171,754 shares in the company, valued at approximately $11,930,032.84. The disclosure for this sale can be found here. 5.80% of the stock is owned by company insiders.
Several institutional investors have recently modified their holdings of MDSO. Brown Capital Management LLC raised its position in shares of Medidata Solutions by 0.6% in the first quarter. Brown Capital Management LLC now owns 5,921,818 shares of the company’s stock valued at $341,630,000 after buying an additional 33,042 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Medidata Solutions by 5.1% in the first quarter. Vanguard Group Inc. now owns 4,874,974 shares of the company’s stock valued at $281,237,000 after buying an additional 235,190 shares during the last quarter. Clearbridge Investments LLC raised its position in shares of Medidata Solutions by 61.4% in the first quarter. Clearbridge Investments LLC now owns 2,449,038 shares of the company’s stock valued at $141,285,000 after buying an additional 931,729 shares during the last quarter. Champlain Investment Partners LLC raised its position in shares of Medidata Solutions by 11.5% in the first quarter. Champlain Investment Partners LLC now owns 1,653,230 shares of the company’s stock valued at $95,375,000 after buying an additional 169,870 shares during the last quarter. Finally, State Street Corp raised its position in shares of Medidata Solutions by 17.1% in the first quarter. State Street Corp now owns 1,432,120 shares of the company’s stock valued at $82,615,000 after buying an additional 209,074 shares during the last quarter.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.